IL-2 and Semaglutide for Alzheimer's Disease
This study is looking at whether a combination of Interleukin-2 (IL-2) and Semaglutide might be safe and helpful for people with Alzheimer's disease. Researchers believe that inflammation in the brain plays a role in Alzheimer's, and that IL-2 can help restore immune cells (regulatory T cells) that control inflammation. Semaglutide is a drug already used for diabetes and obesity. This study will enroll 30 participants between 50 and 86 years old who have probable Alzheimer's disease and specific blood test results. The main goal is to see if these treatments are safe and well-tolerated over a 6-month period.
- Study design
- This is an interventional study with 30 planned participants. It will compare IL-2 alone, Semaglutide plus IL-2, and a placebo (an inactive substance).
- What's involved
- Participants would receive aldesleukin (IL-2) subcutaneously (under the skin) once daily for 5 days, repeated every 4 weeks for six cycles. Some participants will also receive subcutaneous semaglutide. The treatment phase lasts 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is to assess safety and tolerability during the 6-month treatment phase. Further follow-up beyond this period is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07651319
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Recruiting
PHASE1Ages 50–86InterventionalTreatmentThe Methodist Hospital Research InstituteInvestigator-initiated
~30 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:IL-2 (Aldesleukin)Semaglutide Plus IL-2Placebo
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the safety and the tolerability of IL-2 plus Semaglutide in AD patients
Measured over 6 months treatment phase
Conditions
Where it's being run
1 sites across 1 statesTexas1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of probable Alzheimer disease according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria13.
Male or female age 50 to 86 years
MMSE between 16-26
Albumin greater than or equal to 3.0mg/dL
White Blood Count (WBC) \>3,500/mm3; platelets \>100,000/mm3; hematocrit (HCT) \>32%.
INR\<1.4
If on medications affecting cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 4 weeks prior to screening and should remain at a stable dosage during the course of the study.
English language speaking
Formal education of eight or more years
Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening
A family member or caretaker who is expected to be consistently available, administer study drugs of IL-2 and attend study visits throughout the study.
For AD patients with limited decision-making capacity, the legally authorized representative (LAR) should be present and consent based on the patient's best interest.
Exclusion
Any untreated bacterial, fungal or viral infection
Renal dysfunction indicated by serum creatinine greater than 1.5 mg/dL
Hepatic impairment indicated by Alanine aminotransferase level (ALT) and aspartate aminotransferase (AST) greater than two times normal
Clinically significant pulmonary dysfunction, including a history of chronic pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\]) associated with functional limitation, or FEV₁ \< 75% of predicted for age and height when pulmonary function testing indicated to evaluate ongoing respiratory symptoms
Clinically significant cardiac dysfunction, including a history of uncontrolled cardiac arrhythmias, prior cardiac tamponade, or unstable angina or myocardial infarction within 3 months prior to screening, or clinically significant abnormalities on baseline electrocardiogram (ECG). LVEF\< 40% in echocardiography if clinically indicated based on ongoing cardiac symptoms or abnormal ECG findings
Hypersensitivity or allergy to IL-2
History of severe gastrointestinal disease Hospitalization or change of chronic concomitant medication within one month prior to screening.
History of hemorrhage or infarct or \> 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor with the exception of small incidental meningiomas) in prior CT or MRI.
Clinical or laboratory findings consistent with:
Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:
History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
History of acute/chronic hepatitis B or C and/or carriers of hepatitis B
History of organ allografts
Current treatment with insulin or insulin secretagogues (including sulfonylureas or meglitinides)
Prior GLP-1 RA administration or natural GLP1 supplements intake within the past 6 months
Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc.).
Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents (except risperidone ≤1.5 mg/day, quetiapine ≤100 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day), antiepileptics (except lamotrigine, gabapentin and pregabalin for nonseizure indications), centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), opiate analgesics, systemic corticosteroids, psychostimulants, antiparkinsonian medications (except for non-parkinsonian indications) and mood stabilizers (e.g., valproate, lithium), sedatives, and anxiolytics with the exception that use of short- to medium-acting benzodiazepines for treatment of insomnia is permitted, however, use of sedatives or hypnotics should be avoided for 8 hours before administration of cognitive tests.
Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine.
Use of concomitant CYP-metabolized medications with a narrow therapeutic index including warfarin, calcineurin inhibitors, or theophylline)
Suspected or known drug or alcohol abuse, i.e., more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) indicated by elevated MCV significantly above normal value at screening
Suspected or known allergy to any components of the study treatments.
Intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer.
Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; INR \>1.4 or other coagulopathy; platelet count of \<100,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
Any condition, which in the opinion of the investigator makes the patient unsuitable for inclusion.
What this trial measures
- To assess the safety and the tolerability of IL-2 plus Semaglutide in AD patients6 months treatment phase
Number of participants with adverse events and with abnormal laboratory findings (serum chemistry, hematology).